Does Accelerated Approval Deliver Accelerated Access?

EXPERIENCES, CHALLENGES AND PRIORITIES

at ISPOR 20th Annual European Congress

13:00-14:00  |  8th November
Lomond Auditorium, Loch Suite, Scottish Event Campus

An educational symposium featuring short presentations from a panel of experts, followed by an interactive Q&A session with the audience.

Panos Kanavos
Associate Professor in International Health Policy, London School of Economics and Political Science

Victoria Tzouma
Associate Director in Health Economics and Policy, London School of Economics and Political Science

Kate Morgan
Policy and Public Affairs Manager, Myeloma Patients Europe

Chris Hoyle
Director Health Economics & Payer Analytics, AstraZeneca

Sponsored by AstraZeneca
Hosted by The London School of Economics and Political Science
Accelerated regulatory pathways have the potential to dramatically change the treatment paradigm for a number of conditions. However, rapid regulatory approval does not guarantee rapid patient access.

This symposium will explore ongoing London School of Economics (LSE) research into the impact of HTA and value assessment on cancer drugs approved through accelerated pathways. Differences in approach and evidence requirements will be discussed and representatives from industry, academia and patient groups will share experiences and perspectives.

The audience will be invited to contribute their thoughts on the existing challenges and determine priorities for ensuring sustainable solutions that provide appropriate patient access to innovative treatments.

This symposium was convened with financial support from AstraZeneca. Panellists Panos Kanavos, Victoria Tzouma and Kate Morgan retained editorial control over all presentation materials and content and the views or opinions expressed by them are not necessarily those of AstraZeneca.

<table>
<thead>
<tr>
<th>Time</th>
<th>Content</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>Chair’s welcome and introductions</td>
<td>Victoria Tzouma</td>
</tr>
<tr>
<td>13.05</td>
<td>Are Accelerated Approval Mechanisms a Predictor to Early Access and Coverage?</td>
<td>Panos Kanavos</td>
</tr>
<tr>
<td>13.15</td>
<td>Analytical Approaches and Practical Challenges – Industry perspectives from a recent example</td>
<td>Chris Hoyle</td>
</tr>
<tr>
<td>13.25</td>
<td>Meeting Patient Expectations of Accelerated Approval</td>
<td>Kate Morgan</td>
</tr>
<tr>
<td>13.35</td>
<td>Discussion and interactive Q&amp;A</td>
<td>Moderated by Victoria Tzouma</td>
</tr>
</tbody>
</table>

This symposium is part of a London School of Economics research project supported by AstraZeneca. The findings will be published in summer 2018.